Adamis Pharmaceuticals Corp., of San Diego, said it received a complete response letter from the FDA regarding its new drug application (NDA) for Epinephrine Injection USP 1:1000 0.3 mg pre-filled single-dose syringe for emergency use in acute anaphylaxis. The NDA was filed May 28, 2014. The FDA raised questions about the volume of dosage that the syringe delivers, including what is claimed in the label and what is required by the FDA. Adamis said it will request a meeting. Adamis' stock (NASDAQ:ADMP) lost 53.8 percent, to close at $4.09 on Monday.